> Detailanzeige

Gerhardt, Kristin [Verfasser:in]; Jentzsch, Madlen [Verfasser:in]; Georgi, Thomas [Verfasser:in]; Sretenovi´c, Aleksandra [Verfasser:in]; Cross, Michael [Verfasser:in]; Bach, Enrica [Verfasser:in]; Monecke, Astrid [Verfasser:in]; Leiblein, Sabine [Verfasser:in]; Hoffmann, Sandra [Verfasser:in]; Todorovi´c, Milena [Verfasser:in]; Bila, Jelena [Verfasser:in]; Sabri, Osama [Verfasser:in]; Schwind, Sebastian [Verfasser:in]; Franke, Georg-Nikolaus [Verfasser:in]; Platzbecker, Uwe [Verfasser:in]; Vucˇ ini´c, Vladan [Verfasser:in]

Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells—Report on Two Cases
  • Beteiligte: Gerhardt, Kristin [Verfasser:in]; Jentzsch, Madlen [Verfasser:in]; Georgi, Thomas [Verfasser:in]; Sretenovi´c, Aleksandra [Verfasser:in]; Cross, Michael [Verfasser:in]; Bach, Enrica [Verfasser:in]; Monecke, Astrid [Verfasser:in]; Leiblein, Sabine [Verfasser:in]; Hoffmann, Sandra [Verfasser:in]; Todorovi´c, Milena [Verfasser:in]; Bila, Jelena [Verfasser:in]; Sabri, Osama [Verfasser:in]; Schwind, Sebastian [Verfasser:in]; Franke, Georg-Nikolaus [Verfasser:in]; Platzbecker, Uwe [Verfasser:in]; Vucˇ ini´c, Vladan [Verfasser:in]
  • Erschienen: Lausanne: Frontiers Research Foundation, [2023]
  • Erschienen in: Frontiers in oncology ; 11, (2021)
  • Sprache: Englisch
  • Schlagwörter: polatuzumab vedotin ; PMBCL ; CAR (chimeric antigen receptor) T cells ; allogeneic hematopoeitic stem cell transplantation ; DLBCL
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigenreceptor (CAR) T-cell therapy experience treatment failure and subsequently have a poorprognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains apotentially curative approach for patients in this situation. Induction of a deep responseprior to alloHSCT is crucial for long-term outcomes, but the optimal bridging strategyfollowing relapse after CAR T-cell therapy has not yet been established. Polatuzumabvedotin, an antibody drug conjugate targeting CD79b, is a novel treatment option for use incombination with rituximab and bendamustine (Pola-BR) in relapsed or refractory disease.Patients: We report two heavily pretreated patients with primary refractory diffuse large Bcelllymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) respectivelywho relapsed after therapy with CAR T-cells with both nodal and extranodalmanifestations of the disease. After application of three courses of Pola-BR bothpatients achieved a complete metabolic remission. Both patients underwent alloHSCTfrom a human leukocyte antigen (HLA)-mismatched donor following conditioning withbusulfan and fludarabine and are disease free 362 days and 195 days after alloHSCTrespectively. We conclude that Pola-BR can be an effective bridging therapy beforealloHSCT of patients relapsing after CAR T-cell therapy. Further studies will be necessaryto define the depth and durability of remission of this salvage regimen before alloHSCT.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Namensnennung (CC BY)